(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 May 2007 (03.05.2007)

PCT

(10) International Publication Number
WO 2007/048779 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61K 31/501* (2006.01)
C07D 409/14 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/EP2006/067696

(22) International Filing Date: 24 October 2006 (24.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

05110028.7	26 October 2005 (26.10.2005)	EP
06100209.3	10 January 2006 (10.01.2006)	EP
06101545.9	10 February 2006 (10.02.2006)	EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DE BRUYN, Marcel, Frans, Leopold** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **MACDONALD, Gregor, James** [GB/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KENNIS, Ludo, Edmond, Josephine** [BE/BE]; Bosstraat 35, B-2500 Lier (BE). **LANGLOIS, Xavier, Jean, Michel** [FR/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN DEN KEYBUS, Frans, Alfons, Maria** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN ROOSBROECK, Yves, Emiel, Maria** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS

(57) **Abstract:** The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

WO 2007/048779 A1